Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study-Reference-Cited by-同舟云学术

Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Phillips Emma C.¹^ORCID,Warren Cirle A.²,Ma Jennie Z.³,Madden Gregory R.²^ORCID

Affiliation:

1. University of Virginia School of Medicine, Charlottesville, Virginia, USA

2. Division of Infectious Diseases & International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA

3. Department of Public Health Sciences, University of Virginia Health System, Charlottesville, Virginia, USA

Abstract

This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25–3.12; P = 0.853).

Funder

HHS | NIH | National Center for Advancing Translational Sciences

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00001-22

Reference23 articles.

1. Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection

2. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence